Articles

In vivo stabilization of a less toxic asparaginase variant leads to a durable anti-tumor response in acute leukemia

Cancer Research Institute Ghent (CRIG), Ghent, Belgium; Department of Biomolecular Medicine, Ghent University, Ghent, Belgium; Department of Diagnostic Sciences, Ghent University, Ghent
Department of Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago
Cancer Research Institute Ghent (CRIG), Ghent, Belgium; Department of Biomolecular Medicine, Ghent University, Ghent, Belgium; Department of Imaging and Pathology, KU Leuven, Leuven
Department of Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago
Cancer Research Institute Ghent (CRIG), Ghent, Belgium; Department of Biomolecular Medicine, Ghent University, Ghent
Cancer Research Institute Ghent (CRIG), Ghent, Belgium; Department of Pediatric Hemato-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent, Belgium; Department of Internal Medicine and Pediatrics, Ghent University, Ghent
Cancer Research Institute Ghent (CRIG), Ghent, Belgium; Department of Diagnostic Sciences, Ghent University, Ghent
Department of Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago
Department of Pharmaceutical Sciences, College of Pharmacy, University of Illinois at Chicago (UIC), Chicago, Illinois 60612, United States; Biophysics Core at Research Resources Center, University of Illinois at Chicago (UIC), Chicago, Illinois 60607
Metabolomics Core Facility, Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054
Metabolomics Core Facility, Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054
Cancer Research Institute Ghent (CRIG), Ghent, Belgium; Department of Pediatric Hemato-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent
Cancer Research Institute Ghent (CRIG), Ghent, Belgium; Department of Pediatric Hemato-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent, Belgium; Department of Internal Medicine and Pediatrics, Ghent University, Ghent
Cancer Research Institute Ghent (CRIG), Ghent, Belgium; Department of Pediatric Hemato-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent, Belgium; Department of Internal Medicine and Pediatrics, Ghent University, Ghent
Cancer Research Institute Ghent (CRIG), Ghent, Belgium; Department of Diagnostic Sciences, Ghent University, Ghent
Cancer Research Institute Ghent (CRIG), Ghent, Belgium; Department of Biomolecular Medicine, Ghent University, Ghent
Department of Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago, USA; The Jesse Brown VA Medical Center, Chicago, IL
Haematologica Early view Aug 18, 2022 https://doi.org/10.3324/haematol.2022.281390